Regulatory Affairs Specialist – Biocides
Enregistrez cette offre et organisez votre recherche
Créez un compte gratuit pour enregistrer des offres d'emploi, créer des alertes et revenir à cette liste depuis votre tableau de bord.
En continuant, vous acceptez nos Conditions d’utilisation & Politique de confidentialité.
Arche Consulting in België zoekt een Regulatory Affairs Professional met expertise in risicoanalyse en analytische chemie om deel uit te maken van een multidisciplinair team dat werkt binnen EU-regelgeving voor biociden en aanverwante chemische dossiers.
Je stelt regulatorische dossiers op, ondersteunt projecten, vertaalt complexe vereisten naar heldere adviezen en onderhoudt contacten met autoriteiten en klanten. De functie biedt ruimte voor professionele groei en een competitief salarispakket.
-
Regulatory Affairs Manager
Il y a 12 heures
Oost-Vlaanderen, Oost-Vlaanderen, Belgique Kintiga Temps plein 65 000 € - 90 000 € ContratWe are Kintiga, a pan-European specialist that partners with ambitious health technology developers through the complex journey to achieve successful patient access across Europe, with our tailored approach, global perspective and local expertise. Kintiga unites three companies: MAP Patient Access (UK), AxTalis (Benelux), and SKC Consulting (Germany).We’re...
-
Project Toxicologist
Il y a 2 jours
Oost-Vlaanderen, Oost-Vlaanderen, Belgique Argenx Temps plein 80 000 € - 110 000 € ContratJoin us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the potential to...
-
Project Toxicologist
Il y a 5 jours
Oost-Vlaanderen, Oost-Vlaanderen, Belgique argenx SE Temps plein 80 000 € - 110 000 € ContratAbout the roleJoin us as we transform immunology and deliver medicines that help autoimmune patients get their lives back. argenx is preparing for multi-dimensional expansion to reach more patients through a rich pipeline of differentiated assets, led by VYVGART, our first-in-class neonatal Fc receptor blocker approved for the treatment of gMG, and with the...